Articles tagged with Alzheimer Disease
A clinical trial is underway at the University of Colorado to test a drug that could improve memory and learning in those with Down syndrome. The study, led by Dr. Alberto Costa, aims to enhance brain function and potentially increase hope for those affected.
The studies focus on positron emission tomography (PET) to differentiate between types of dementia and identify pharmaceuticals to slow dementia progression. PET scores provide a valid biomarker for monitoring Alzheimer's disease progression.
Researchers at the University of Bristol have received a major funding boost to continue their research into the pathological processes underpinning Alzheimer's disease. They have found that neuronal excitability is substantially altered in the model of Alzheimer's disease, leading to changes in action potential generation and waveform.
Over 85% of respondents want to see a doctor if they exhibit confusion and memory loss, while nearly half believe there is a reliable medical test for early-stage diagnosis. Public interest in predictive testing also prevails, with two-thirds wanting to know their Alzheimer's risk before symptoms appear.
A Johns Hopkins University study found that an existing anti-seizure drug improves memory and brain function in adults with a form of cognitive impairment. The findings suggest that the drug may slow the abnormal loss of brain function in some aging patients before their condition becomes Alzheimer's.
Researchers have identified detectable changes in biological markers in the spinal fluid up to 20 years before dementia onset. Participants with inherited Alzheimer's mutations exhibit lower amyloid beta and higher tau protein levels in their cerebrospinal fluid, indicating potential for prevention trials.
The investigational amyloid imaging agent [18F]Flutemetamol showed highly consistent image interpretation and comparable in vitro binding to Pittsburgh Compound-B, according to recent clinical research data. Flutemetamol is being studied for the detection of beta amyloid using PET brain scans.
Researchers at University of Western Ontario will investigate whether prion protein is a therapeutic target in Alzheimer's disease. The team aims to test their hypothesis on the interaction between prion protein and amyloid beta, which could lead to novel therapeutics for both Prion diseases and Alzheimer
A recent study suggests that seven potentially modifiable risk factors, including smoking and physical inactivity, contribute to an estimated half of all Alzheimer's disease cases worldwide. By reducing these risk factors by 25%, up to 3 million cases of AD could be prevented globally.
A study by Deborah Barnes found that low education, smoking, physical inactivity, depression, mid-life hypertension, diabetes, and mid-life obesity are associated with up to 51% of Alzheimer's cases worldwide. Lifestyle changes such as increasing physical activity and quitting smoking could potentially prevent some cases.
A study found that participants with high levels of amyloid plaques, a hallmark of Alzheimer's, had twice the typical annual rate of falls for their age group. This suggests that falls may be an early indicator of Alzheimer's disease in people with preclinical symptoms.
A Loyola University Health System study found that 35% of retired NFL players had scores suggesting possible mild cognitive impairment (MCI), which can be a precursor to Alzheimer's disease. The average age of the players was 61, and their impairments were highly similar to those exhibited by patients with MCI.
Researchers have identified how the SorCS1 gene controls amyloid-beta generation in the brain, contributing to both Alzheimer's disease and type 2 diabetes. The study reveals that SorCS1 regulates the movement of amyloid precursor protein (APP) within cells.
Researchers found abnormal tau tangles and amyloid-beta plaques in survivors years after a single TBI, suggesting a potential link between the two conditions. The study suggests that a single TBI may initiate long-term neurodegenerative processes, offering new insights into the development of Alzheimer's disease.
Researchers from NYU Langone Medical Center presented new research at the 2011 Alzheimer's Association International Conference. The study found that retired NFL players are more likely to experience mild cognitive impairment than expected, suggesting a possible link between repetitive head trauma and late-life cognitive disorders. Add...
The Gladstone Institutes have announced a Center for Comprehensive Alzheimer's Disease Research, which aims to develop therapies for Alzheimer's. The center will focus on identifying drug targets and candidates, leveraging collaborations with other institutions and companies.
A recent study suggests that keeping up with general health factors, such as denture fit, vision, and hearing, may reduce the risk of developing dementia. The study found that each health problem increased a person's odds of developing dementia by 3.2 percent compared to those without such problems.
Rice University researchers have created a metallic molecule that becomes strongly photoluminescent when it attaches to amyloid fibrils, which form plaques in the brains of Alzheimer's patients. This breakthrough technique has the potential to improve the design of medications to treat the devastating disease.
A previously understudied amyloid peptide, A-beta-43, is more abundant and neurotoxic than previously studied peptides in promoting Alzheimer's disease. The findings suggest a potential role for A-beta-43 as a biomarker for diagnosis and a new approach for preventing AD-causing amyloidosis.
Scientists have developed a sensor to detect zinc in zebrafish, which could help understand the role of zinc in diseases like type 2 diabetes, prostate cancer, and Alzheimer's. The new technology has been successfully tested and is expected to aid further research into these conditions.
Scientists have identified new proteins in human cerebrospinal fluid that may help diagnose Alzheimer's disease earlier and develop effective treatments, offering hope for patients and their families affected by the condition.
Researchers discovered a compound in cinnamon bark that can inhibit the development of Alzheimer's disease. The extract, called CEppt, slows down the progression of the disease and breaks up toxic amyloid fibers in the brain.
A new study found that a protein called soluble amyloid precursor protein beta (sAPPβ) may be a more accurate predictor of Alzheimer's disease than existing biomarkers. The researchers discovered that sAPPβ levels were significantly higher in participants who developed the disease, with an average of 1,200 nanograms per milliliter.
Scientists create 'molecular cap' that prevents amyloid fiber formation, a key process in both Alzheimer's disease and HIV transmission. The breakthrough brings hope for delaying Alzheimer's onset and preventing sexual transmission of HIV.
A new study found that an unknown component of coffee interacts with caffeine to increase blood levels of a growth factor called GCSF, which fights off the Alzheimer's disease process. This boost is associated with improved memory and reduces the risk of cognitive decline.
Scientists have identified a protective mechanism that tries to collect and detoxify high levels of toxic amyloid beta peptide found in Alzheimer's disease. The molecular chaperone HspB1 works like a waste management company to protect brain cells from damage.
Structural biologists at CSHL have obtained a precise molecular map of an allosteric inhibitor's binding site in the GluN1/GluN2B NMDA receptor subtype. This discovery enables the design of highly specific compounds with minimal side effects for treating neurological diseases.
Researchers used a brain scan to assess amyloid plaques and neurofibrillary tangles in adults with Down syndrome, revealing higher levels in all brain regions compared to healthy controls. The study found significant associations between increased age and higher binding values in specific brain areas.
A study found that a low-saturated fat and low-glycemic index diet decreased certain biomarkers of Alzheimer's disease in healthy adults, while also improving memory performance. However, the diet had the opposite effect on individuals with mild cognitive impairment, potentially due to its short duration.
Researchers are advancing positron emission tomography (PET) as an effective method of early detection for Alzheimer's disease. Studies show that amyloid plaques build up slowly and are often present in healthy older individuals, with significant buildup linked to quicker memory decline and brain atrophy.
A new study suggests that weight loss due to bariatric surgery may reduce the risk of Alzheimer's disease by lowering the expression of genes related to the condition. After a significant weight loss, patients showed a 22% decrease in amyloid precursor protein expression and a 31% decrease in messenger RNA for APP.
A new slow-release compound, JM6, protects mice against neurodegenerative effects of Huntington's and Alzheimer's disease by increasing production of a neuroprotective compound. JM6 extends lifespan, improves motor coordination and preserves synapses in both models.
Researchers have identified a compound called JM6 that diminishes the effects of both diseases in animal models, preventing memory deficits and loss of synaptic connections. The compound works by inhibiting an enzyme linked to neurodegenerative diseases, suggesting a potential therapeutic breakthrough.
Researchers have discovered a potential new therapy for Alzheimer's disease, with the cysteine protease inhibitor E64d improving memory deficits and reducing β-amyloid build-up. The study suggests that increasing Cathepsin B activity is not detrimental to memory function, contrary to previous assumptions.
Researchers have identified a small noncoding RNA that promotes the production of an alternative splice variant of KCNIP4, leading to neurodegeneration and potential disruption in beta-amyloid processing. Elevated levels of this RNA were found in brain cells from Alzheimer's disease patients.
Researchers have expanded on existing knowledge of Alzheimer's disease by identifying a novel location within the MS4A gene cluster associated with the condition. The study suggests that the immune system plays a key role in its progression, with several genes implicated in allergies and autoimmune diseases.
Researchers at TGen found that naturally occurring plant compounds could slow down Alzheimer's disease by inhibiting a protein linked to memory loss. Harmine and other beta-carboline alkaloids show promise as therapeutic drugs, targeting tau phosphorylation and neurofibrillary tangles.
Researchers at Stanford University School of Medicine developed a new fMRI technique that can distinguish between different mental states based on synchronized brain network activity. The study used a novel approach to capture brain activity in real-world, self-paced conditions, allowing for more accurate identification of brain states.
Researchers have discovered that proteins in Alzheimer's fibrils can recycle and detach, potentially leading to new therapeutic strategies. The study found that Aβ40 molecules recycle more frequently than Aβ42, suggesting a potential target for modulating recycling and treating the disease.
A €6m European Commission grant will fund clinical trials of NILVADIPINE, a medication already used to treat high blood pressure, in treating Alzheimer's disease. The trials aim to improve memory and slow the progression of Alzheimer's disease.
A new study published in Neurology suggests that more than half of people diagnosed with Alzheimer's disease before age 60 are initially misdiagnosed due to atypical symptoms. Researchers found that 53% of those with no memory problems were incorrectly diagnosed, highlighting the need for biomarkers to improve diagnosis and treatment.
A new study published in Neurobiology of Aging suggests that the pathological forms of amyloid beta and tau proteins may collude to decrease the survival of brain cells. This finding raises hopes for early markers and treatment strategies to combat the disease by targeting mitochondrial dysfunction.
Researchers have created a new X-ray method called SAXS-CT to map the myelin sheaths of nerve cells in detail. This can provide insights into neurodegenerative diseases such as cerebral malaria, multiple sclerosis, and Alzheimer's disease.
A recent report from the National Institutes of Health found insufficient evidence linking modifiable factors to Alzheimer's disease risk. The panel concluded that large-scale studies and clinical trials are needed to answer these questions. Researchers urge individuals to maintain a healthy lifestyle despite current uncertainty.
The Einstein Aging Study will explore the relationship between cognitive and motor aging, as well as pain and stress, as novel risk factors for Alzheimer's. Researchers will assess biomarkers, genes, and neuro-imaging procedures to facilitate earlier diagnosis, prevention, and treatment of Alzheimer's disease.
According to a recent report, dementia and mild cognitive impairment are prevalent among 'oldest old' women, who are 85 years of age and older. The prevalence of these conditions increases with age, with the highest rates found in women over 90 years old.
A new blood test has been developed to diagnose Alzheimer's disease at an early stage using biochemical analysis of dehydroepiandrosterone (DHEA) production. The test was able to accurately detect the disease with small samples of blood and differentiate it from other types of dementia.
Researchers found that higher cell chatter in affected regions boosts amyloid beta levels, contributing to plaque formation. Studies on mice suggest reducing activity in these regions may help prevent Alzheimer's plaques.
Researchers discovered that excess beta amyloid protein clogs cell transport motors, causing abnormal cell division and defective neurons. The study suggests a new target for Alzheimer's treatment, allowing the brain to regenerate properly.
Early-onset Alzheimer's disease can be identified through PET-CT examinations, which reveal a 'cognitive reserve' that slows symptom expression. This discovery supports earlier diagnosis and education to improve patient outcomes.
A new study reveals that clock genes function in multiple areas of the human brain, affecting sleep patterns and cognitive function in Alzheimer's patients. The findings have significant implications for understanding and treating sleep disturbances associated with the disease.
Researchers found cotinine reduced Alzheimer's disease brain plaques and prevented memory loss in mice, showing promising results for a potential therapy. Cotinine also stimulated the survival of neurons and enhanced attention and memory.
Researchers at the University of Strathclyde have developed a new technique that can detect Alzheimer's disease earlier than current methods. This approach uses fluorescence signals to identify clusters of peptide associated with the disease, allowing for potential treatment development and screening patients without needles or wires.
The National Institute on Aging/Alzheimer's Association Diagnostic Guidelines for Alzheimer's Disease outline new approaches for clinicians and researchers. The guidelines cover the full spectrum of the disease, including preclinical stages, mild cognitive impairment, and dementia due to Alzheimer's pathology.
Researchers found that thinner brain areas associated with Alzheimer's can predict dementia and disease development. The study analyzed MR images from two groups, revealing a threefold increased risk of Alzheimer's among those with the thinnest cortical areas.
Researchers found that treating vascular risk factors can help slow memory decline and reduce the risk of developing dementia. Those receiving full treatment were 39% less likely to develop Alzheimer's disease compared to those receiving no treatment.
A new study found that areas of the brain affected by Alzheimer's disease may start shrinking up to a decade before dementia is diagnosed. The researchers used MRI scans to measure brain size in people with no memory problems and followed them for years to see who developed the disease.
A systematic review of memantine trials found no evidence of benefit for patients with mild Alzheimer's disease, contradicting its frequent off-label use. Increasing acetylcholine levels appears to slow mental decline in AD, but current evidence is insufficient.
A new MRI study published in Radiology suggests that automated brain volume measurements can predict future memory decline in elderly people with normal cognitive ability. The study found high accuracy rates when considering multiple brain regions, including the temporal and parietal lobes.
A study published in Radiology used MRI to analyze brain atrophy and identify individuals with mild cognitive impairment at risk of progressing to Alzheimer's disease. The researchers found that patients with MCI had a one-year risk of conversion to AD ranging from three to 40 percent.